Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
The deal grants the Chinese pharmaceutical company Novamed the exclusive rights to submit a registration application for the Chinese market för Abstral, a product developed by Orexo, to treat break-through pain in cancer patients. Novamed will also conduct the clinical study program required for a Chinese market registration. After registration Novamed will market and sell the product in China.

To Orexo the deal is worth up to MUSD 4.75, partly as an initial fee and partly as milestone payments. Orexo is also granted a non-disclosed part of the future sales.

The deal is a first step into one of the fastest growing pharmaceutical markets of the world.

"Novamed have an experienced marketing- and sales organization with a sales force of 400 and a broad product portfolio for treatment of cancer. This makes the company an ideal partner for us in China,” states Torbjörn Bjerke, CEO of Orexo.
Kommentera en artikel
Meddela redaktionen
Se alla medlemsnyheter
Mest läst
Senaste nytt
Se senaste nytt
Utvalda artiklar
Utvalda nyheter från förstasidan
Vicore tar in 200 miljoner — utvecklar behandling mot lungfibros
Stororder till samarbetspartner kan bli bingo för Raysearch
Ny Sverigechef till Boehringer Ingelheim
FDA kräver indraget tillstånd för Oncopeptides i USA
Uppmärksamheten kring ALS ger pengar till hennes forskning
Spago startar klinisk studie i endometrios
Andra Nordiska Medier
MedTech Magazine

Sänd till en kollega